Finalist battles prices confinement.docVIP

 PAGE \* MERGEFORMAT 4 Finalist battles prices confinement Pushed a stack of information on hand, the Tian Jialun close your eyes and rubbed his eyebrows, the brain actually still thinking about drug directory varieties selected for the new base pricing. Look at the clock on the table, expect the next how to participate in the provincial-based drug tender, the Tian Jialun need to make accurate judgments. Recently, after the announcement of the new directory, begin to weigh their product pricing in charge of much more than Simcere marketing efforts a. Interview, the majority of the short-listed companies according to market research specific adjustments. Side is the temptation of eating the market, while the risk of price is likely to face two ‘may’ intertwined pharmaceutical companies are caught in between the opportunities and challenges. Their knot that after the implementation of the 2009 version of the base drug directory-based medicine prices fell by an average of 30%, the 2012 version of the new base drug prices affects how corporate nerve. China Pharmaceutical Industry Research and Development Association executive president of Song Ruilin-based medicine should be priced based on the value of drugs to be used with caution in the administrative price cuts and low-cost bid. ‘ Exclusive varieties worry price A substantial increase in the category as a new basic medicine catalog, exclusive varieties of price adjustment is still complicated and confusing. Worried exclusive drugs lower prices, the industry is still waiting to see specific price adjustment policies. ‘We are now most worried about is the exclusive varieties pricing problem.’ Baiyun Mountain in Guangzhou Qixing Pharmaceutical Marketing Director Tang King praise not mince words. The Qi Xing selected based medicine directory exclusive varieties are the Hua Tuo Zaizao, and directory cycle, the product overall sales growth of more than 50%. Deng Jing Chan knew that raw material costs